New drug cocktail aims to tackle tough lymphoma

NCT ID NCT07272499

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study is testing a combination of three drugs—orelabrutinib, lisaftoclax, and rituximab—in people with untreated, high-risk mantle cell lymphoma (MCL). The goal is to see how well this treatment shrinks or eliminates cancer. The trial will enroll 25 participants and track response rates, survival, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orelabrutinib, lisaftoclax, and rituximab
What this could lead to: If successful, this combination could offer a new, effective first-line treatment option for people with high-risk mantle cell lymphoma, potentially improving response rates and survival.
What could go wrong: This is a small, early-phase (phase 2) trial with only 25 participants, so results may not apply to everyone. Side effects from the drug combination are possible, and the treatment may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA (MCL)

Contacts and locations

Locations

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.